{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:10:53Z","timestamp":1790604653814,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1684\/bdc.2014.2048","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T15:58:43Z","timestamp":1565711923000},"page":"1048-1058","source":"Crossref","is-referenced-by-count":3,"title":["La leuc\u00e9mie \u00e0 plasmocytes"],"prefix":"10.1016","volume":"101","author":[{"given":"Aur\u00e9lie","family":"Ravinet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques Olivier","family":"Bay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Tournilhac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2014.2048_bib0005","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archinte.133.5.813","article-title":"Plasma cell leukemia. Report on 17 cases","volume":"133","author":"Kyle","year":"1974","journal-title":"Arch Intern Med"},{"key":"10.1684\/bdc.2014.2048_bib0010","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1365-2141.1994.tb05114.x","article-title":"Primary plasma cell leukaemia","volume":"88","author":"Dimopoulos","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1684\/bdc.2014.2048_bib0015","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood.V93.3.1032","article-title":"Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics","volume":"93","author":"Garc\u00eda-Sanz","year":"1999","journal-title":"Blood"},{"key":"10.1684\/bdc.2014.2048_bib0020","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1002\/cncr.24700","article-title":"Primary plasma cell leukemia: a surveillance, epidemiology, and end results database analysis between 1973 and 2004","volume":"115","author":"Ramsingh","year":"2009","journal-title":"Cancer"},{"key":"10.1684\/bdc.2014.2048_bib0025","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2008.4","article-title":"Genetic aberrations and survival in plasma cell leukemia","volume":"22","author":"Tiedemann","year":"2008","journal-title":"Leukemia"},{"key":"10.1684\/bdc.2014.2048_bib0030","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0889-8588(05)70125-8","article-title":"Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia","volume":"13","author":"Blad\u00e9","year":"1999","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1684\/bdc.2014.2048_bib0035","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood-2014-03-565051","article-title":"Trends in survival of patients with primary plasma cell leukemia: a population based analysis","volume":"124","author":"Gonsalves","year":"2014","journal-title":"Blood"},{"key":"10.1684\/bdc.2014.2048_bib0040","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/0002-9343(87)90942-9","article-title":"Plasma cell leukemia: an evaluation of response to therapy","volume":"83","author":"Noel","year":"1987","journal-title":"Am J Med"},{"key":"10.1684\/bdc.2014.2048_bib0045","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s12032-007-9011-5","article-title":"Thirty patients with primary plasma cell leukemia: a single center experience","volume":"25","author":"Colovi\u0107","year":"2008","journal-title":"Med Oncol"},{"key":"10.1684\/bdc.2014.2048_bib0050","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000210555","article-title":"A retrospective analysis of thirty-one cases of plasma cell leukemia from a single center in China","volume":"121","author":"Peijing","year":"2009","journal-title":"Acta Haematol"},{"key":"10.1684\/bdc.2014.2048_bib0055","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/annonc\/mdq646","article-title":"Primary plasma cell leukemia: a retrospective multicenter study of 73 patients","volume":"22","author":"Pagano","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2014.2048_bib0060","unstructured":"Usmani SZ, Nair B, Qu P, et al. Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols. Leukemia [Internet] 2012 ; Disponible sur : http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22508408 [cit\u00e9 1er ao\u00fbt 2012]."},{"key":"10.1684\/bdc.2014.2048_bib0065","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/leu.2012.336","article-title":"Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group","volume":"27","author":"Fern\u00e1ndez de Larrea","year":"2012","journal-title":"Leukemia"},{"key":"10.1684\/bdc.2014.2048_bib0070","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/sj.leu.2403647","article-title":"Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment","volume":"19","author":"P\u00e9rez-Andr\u00e9s","year":"2005","journal-title":"Leukemia"},{"key":"10.1684\/bdc.2014.2048_bib0075","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1038\/sj.leu.2401211","article-title":"The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma","volume":"12","author":"Pellat-Deceunynck","year":"1998","journal-title":"Leukemia"},{"key":"10.1684\/bdc.2014.2048_bib0080","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.leukres.2010.04.021","article-title":"Flow cytometric immunophenotypic characteristics of 36 cases of plasma cell leukemia","volume":"35","author":"Kraj","year":"2011","journal-title":"Leuk Res"},{"key":"10.1684\/bdc.2014.2048_bib0085","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/leu.2011.176","article-title":"Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience","volume":"26","author":"Avet-Loiseau","year":"2012","journal-title":"Leukemia"},{"key":"10.1684\/bdc.2014.2048_bib0090","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.V97.3.822","volume":"97","author":"Avet-Loiseau","year":"2001","journal-title":"Blood"},{"key":"10.1684\/bdc.2014.2048_bib0095","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.leukres.2008.06.027","article-title":"Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia","volume":"33","author":"Chang","year":"2009","journal-title":"Leuk Res"},{"key":"10.1684\/bdc.2014.2048_bib0100","unstructured":"Egan JB, Shi CX, Tembe W, et al. Whole genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution and clonal tides. Blood [Internet] 2012 ; Disponible sur : http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22529291 [cit\u00e9 30 juil. 2012]."},{"key":"10.1684\/bdc.2014.2048_bib0105","doi-asserted-by":"crossref","first-page":"11463","DOI":"10.1073\/pnas.90.24.11463","article-title":"Transmembrane neural cell-adhesion molecule (NCAM), but not glycosyl-phosphatidylinositol-anchored NCAM, down-regulates secretion of matrix metalloproteinases","volume":"90","author":"Edvardsen","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1684\/bdc.2014.2048_bib0110","unstructured":"Van de Donk NWCJ, Lokhorst HM, Anderson KC, Richardson PG. How I treat plasma cell leukemia. Blood [Internet] 2012 ; Disponible sur : http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22837533 [cit\u00e9 30 juil. 2012]."},{"key":"10.1684\/bdc.2014.2048_bib0115","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00277-002-0480-5","article-title":"Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia","volume":"81","author":"Vela-Ojeda","year":"2002","journal-title":"Ann Hematol"},{"key":"10.1684\/bdc.2014.2048_bib0120","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1002\/cncr.22700","article-title":"Efficacy and safety of bortezomib in patients with plasma cell leukemia","volume":"109","author":"Musto","year":"2007","journal-title":"Cancer"},{"key":"10.1684\/bdc.2014.2048_bib0125","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ijc.20793","article-title":"Bortezomib is an efficient agent in plasma cell leukemias","volume":"114","author":"Espar\u00eds-Ogando","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1684\/bdc.2014.2048_bib0130","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1093\/annonc\/mdr480","article-title":"Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party","volume":"23","author":"D\u2019Arena","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2014.2048_bib0135","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.clml.2011.06.010","article-title":"Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience","volume":"11","author":"Lebovic","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1684\/bdc.2014.2048_bib0140","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/10428190290006143","article-title":"Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia","volume":"43","author":"Johnston","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1684\/bdc.2014.2048_bib0145","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1046\/j.1365-2141.2002.03537_4.x","article-title":"Efficacy of thalidomide in the treatment of VAD-refractory plasma cell leukaemia appearing after autologous stem cell transplantation for multiple myeloma","volume":"117","author":"Bauduer","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1684\/bdc.2014.2048_bib0150","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1080\/10428190601007570","article-title":"Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center","volume":"48","author":"Petrucci","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1684\/bdc.2014.2048_bib0155","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ncponc1008","article-title":"Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia","volume":"4","author":"Ballanti","year":"2007","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1684\/bdc.2014.2048_bib0160","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/ajh.21495","article-title":"Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: no recurrence with subsequent lenalidomide therapy","volume":"84","author":"Pretz","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1684\/bdc.2014.2048_bib0165","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.leukres.2008.03.013","article-title":"Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia","volume":"32","author":"Musto","year":"2008","journal-title":"Leuk Res"},{"key":"10.1684\/bdc.2014.2048_bib0170","doi-asserted-by":"crossref","first-page":"867380","DOI":"10.1155\/2009\/867380","article-title":"Lenalidomide, melphalan, and prednisone association is an effective salvage therapy in relapsed plasma cell leukaemia","volume":"2009","author":"Guglielmelli","year":"2009","journal-title":"J Oncol"},{"key":"10.1684\/bdc.2014.2048_bib0175","article-title":"Final results of a phase ii study evaluating lenaliomide in combination with low dose dexamethasone as first line therapy for primary plasma cell leukemia","volume":"118","author":"Musto","year":"2011","journal-title":"Blood ASH Annual Meeting Abstracts"},{"key":"10.1684\/bdc.2014.2048_bib0180","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ajh.20272","article-title":"Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature","volume":"78","author":"Saccaro","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1684\/bdc.2014.2048_bib0185","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3324\/haematol.2009.013334","article-title":"Primary plasma cell leukemia and autologous stem cell transplantation","volume":"95","author":"Drake","year":"2010","journal-title":"Haematologica"},{"key":"10.1684\/bdc.2014.2048_bib0190","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/leu.2011.312","article-title":"Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research","volume":"26","author":"Mahindra","year":"2012","journal-title":"Leukemia"},{"key":"10.1684\/bdc.2014.2048_bib0195","article-title":"Has allogeneic transplantation a role in the management of plamsa cell leukemia? A study on behalf of the myeloma subcomittee of the Chronic Leukaemia Working Party of the EBMT","volume":"118","author":"Curly Morris","year":"2011","journal-title":"Blood ASH Annual Meeting Abstracts"},{"key":"10.1684\/bdc.2014.2048_bib0200","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1592\/phco.2005.25.12.1820","article-title":"Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia","volume":"25","author":"Jaskiewicz","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1684\/bdc.2014.2048_bib0205","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/jjco\/hym079","article-title":"Development of solitary plasmacytoma in the internal auditory canal and inner ear after allogeneic hematopoietic stem cell transplantation for plasma cell leukemia","volume":"37","author":"Masuda","year":"2007","journal-title":"Jpn J Clin Oncol"},{"key":"10.1684\/bdc.2014.2048_bib0210","volume":"653","author":"Royer","year":"2013","journal-title":"Blood ASH Annual Meeting Abstracts"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115300151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115300151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T04:19:22Z","timestamp":1602476362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115300151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0007455115300151"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2014.2048","relation":{"is-cited-by":[{"id-type":"doi","id":"10.13070\/rs.fr.2.1468","asserted-by":"object"}]},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}